ArticleJournal of pediatric gastroenterology and nutrition2026
Prevalence of disorders of gut-brain-interaction in pediatric patients with in-remission inflammatory bowel disease: An Italian multicenter study.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter: Nuanced Interpretation of Faecal Calprotectin During Maintenance of Ulcerative Colitis Treatment: Sweet Spots and Pitfalls.Alimentary pharmacology & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesPediatric patients with in-remission inflammatory bowel disease (IBD) often report persistent gastrointestinal symptoms, suggesting a potential overlap with disorders of gut-brain-interaction (DGBIs). While DGBIs affect up to 40% of the general population, their prevalence in quiescent IBD children remains limited. We aimed to evaluate the prevalence and distribution of DGBIs, based on Rome-IV criteria, in children with quiescent IBD compared to healthy controls, identifying demographic, clinical and therapeutic factors associated with DGBIs.
methodsIn this multicenter, prospective, controlled study, in-remission IBD pediatric patients and healthy controls were enrolled completing the Rome IV-Questionnaire. IBD-remission was defined by pediatric ulcerative colitis activity index (PUCAI)/pediatric Crohn's disease activity index scores < 10, normal inflammatory markers and recent endoscopic mucosal healing.
resultsForty-one pediatric patients with IBD in remission and 179 healthy controls were enrolled. DGBIs were found in 41.46% of IBD-patients versus 27.93% of controls (p = 0.089). Functional Dyspepsia was significantly more prevalent in IBD patients (p < 0.001), while irritable bowel syndrome was more frequent among controls, though not significantly (p = 0.466). No differences in DGBI prevalence emerged between Crohn's disease and ulcerative colitis (p = 0.54). At the multivariate analysis, psychological comorbidities (odds ratio [OR] 40.767, p < 0.001) and low weight (0.953, p ≤ 0.001) were significantly associated with DGBIs. Notably, 5-aminosalicylic-acid (ASA) administration was associated with reduced DGBIs likelihood (OR 0.139, p = 0.005).
conclusionsIn our cohort, the overall DGBIs prevalence was numerically but not significantly higher in quiescent-IBD patients compared to controls, while upper gastrointestinal DGBIs were significantly more frequent in IBD patients. Psychological and nutritional factors emerged as strong predictors of DGBIs, while 5-ASA may be associated with lower likelihood of DGBIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.